Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -976.00K | -3.45M | -3.27M | -3.31M | -3.41M | -667.00K |
EBITDA | -199.36M | -134.75M | -141.57M | -143.49M | -128.57M | -62.80M |
Net Income | -186.93M | -138.20M | -134.24M | -138.29M | -127.79M | -62.74M |
Balance Sheet | ||||||
Total Assets | 264.57M | 350.07M | 297.67M | 285.10M | 287.04M | 355.95M |
Cash, Cash Equivalents and Short-Term Investments | 227.02M | 312.02M | 259.72M | 242.66M | 242.72M | 351.21M |
Total Debt | 27.63M | 28.97M | 31.36M | 32.86M | 34.59M | 0.00 |
Total Liabilities | 65.56M | 56.97M | 47.12M | 53.90M | 55.13M | 11.67M |
Stockholders Equity | 199.02M | 293.11M | 250.56M | 231.19M | 231.91M | 344.28M |
Cash Flow | ||||||
Free Cash Flow | -156.26M | -118.02M | -121.33M | -122.83M | -107.76M | -53.55M |
Operating Cash Flow | -156.16M | -118.01M | -121.14M | -116.31M | -106.11M | -53.09M |
Investing Cash Flow | 125.79M | -218.80M | 70.70M | 58.44M | -88.24M | -83.16M |
Financing Cash Flow | 5.35M | 161.21M | 135.52M | 122.91M | 1.79M | 360.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $346.73M | ― | -30.00% | ― | -100.00% | -266.37% | |
56 Neutral | $403.97M | ― | 2152.93% | ― | ― | ― | |
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
47 Neutral | $198.13M | ― | -160.99% | ― | -75.67% | -552.37% | |
47 Neutral | $759.91M | ― | -76.09% | ― | -42.84% | -17.32% | |
45 Neutral | $162.74M | ― | -298.41% | ― | 565.52% | 79.44% | |
38 Underperform | $227.47M | ― | -66.75% | ― | ― | -5.57% |
Annexon Biosciences has appointed William Jones to its Board of Directors, bringing his extensive 30-year experience in the biotechnology industry to the company. This strategic move comes as Annexon prepares for the commercialization of key treatments for Guillain-Barré Syndrome and geographic atrophy, with Jones’ commercial expertise expected to enhance the company’s market positioning and execution of its commercialization strategies.